argenx - Green light for VYVGART® Hytrulo in the USA
Argenx announced FDA approval of the subcutaneous formulation of efgartigimod for the treatment of generalized myasthenia gravis (gMG) patients who are AChR-antibody positive (c. 85% of all gMG cases), similar to VYVGART®.Priced at parity to VYVGART on a net annual revenue basis, the subcu version is expected to provide treatment optionality and convenience for the gMG community, thereby helping to get Efgar earlier in the gMG treatment cascade which will be crucial to ensure further Efgar revenue ramp-up. Besides patients' preference, we expect insurance type to determine a patient's formulation.As a result of this news, we increase our LOA for theArgenx N.V. is a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer. Utilizing its suite of differentiated technologies, Co. is focused on developing product candidates with the potential to be either first-in-class against novel targets or best-in-class against known, but complex, targets in order to treat diseases with a significant unmet medical need.
We are an investment house with Belgian roots founded on more than 150 years of trust.
As a private company owned by long-term committed shareholders, we are independent. Naturally and structurally. Our experts have the knowledge to think and act without bias, and to make decisions that benefit our clients. Today and tomorrow.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.